drug
Camptosar
Marketedupdated 3mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 37 investigational indications.
indications
investigational
Colorectal Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying Camptosar
- phase3A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
- phase3QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- phase1Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
- phase3A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- phase2A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- phase3A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
- phase3SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
- N/AChemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 6, 2027
138 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Oct 15, 2036formulationUS 10456360
- Oct 15, 2036formulationUS 10993914
- Oct 15, 2036formulationUS 12059497
- Aug 19, 2036method-of-use (U-3824)US 11344552
- Jun 12, 2033method-of-use (U-1848)US 10980795
- Jun 12, 2033method-of-use (U-1848)US 11369597
- Jun 12, 2033method-of-use (U-1848)US 12364691
- Jun 12, 2033method-of-use (U-1848)US 9339497
- Jun 12, 2033method-of-use (U-1856)US 9364473
- Jun 12, 2033method-of-use (U-1899)US 9452162
- Jun 12, 2033method-of-use (U-1848)US 9492442
- Jun 12, 2033method-of-use (U-1848)US 9717724
- Aug 29, 2028compositionUS 81478672.0y
- Jan 6, 2027compositionUS 8329213138d
FDA exclusivities (2)
- Feb 13, 2031ODE-463Orphan Drug (7y)4.5y
- Feb 13, 2027I-932Indication (3y)176d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that